Literature DB >> 16137752

Risk grouping in stage IB squamous cell cervical carcinoma.

Gregg Van de Putte1, A Kathrine Lie, Werner Vach, Mark Baekelandt, Gunnar B Kristensen.   

Abstract

OBJECTIVES: To test the Gynecologic Oncology Group (GOG) prognostic criteria (based on stromal invasion, tumor size and vascular invasion) for early squamous cervical carcinoma (SCC) in an independent population and to evaluate the prognostic value of a simpler model.
METHODS: We studied 221 patients who underwent radical hysterectomy and bilateral lymphadenectomy for stage IB SCC between 1987 and 1993. Adjuvant treatment consisting of radiotherapy and/or chemotherapy was given in case of large tumor size, positive lymph nodes or invasion into the parametria. Histological slides from all patients were reviewed by one pathologist.
RESULTS: The GOG criteria divided the patients from our population in a small low risk group (3-year relapse-free rate (RFR) of 100%), a small high risk group (RFR of 57%) and a bigger intermediate risk group (RFR of 80-90%). These results are in good agreement with those of the original publication. A risk model based on 2 of the 3 factors used by the GOG may perform as well as the 3-factor model, especially when allowing interaction. Tumors measuring >2 cm and invading into the outer third of the cervical wall had a 5-year DFS of 56% compared to 93% for tumors measuring < or =2 cm or invading to less then the outer third of the cervical wall.
CONCLUSION: The GOG criteria could be validated in this independent population. A model based on 2 of the 3 factors may perform as good.

Entities:  

Mesh:

Year:  2005        PMID: 16137752     DOI: 10.1016/j.ygyno.2005.05.026

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

1.  Patterns of care in patients with cervical cancer 2012: results of a survey among German radiotherapy departments and out-patient health care centers.

Authors:  S Marnitz; C Köhler; A Rauer; A Schneider; V Budach; A Tsunoda; M Mangler
Journal:  Strahlenther Onkol       Date:  2013-07-27       Impact factor: 3.621

2.  Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.

Authors:  Mika Okazawa-Sakai; Takanori Yokoyama; Etsuko Fujimoto; Shinichi Okame; Yuko Shiroyama; Takashi Yokoyama; Kazuhiro Takehara
Journal:  Int J Clin Oncol       Date:  2018-02-14       Impact factor: 3.402

3.  Prognostic Value and Potential Role of Alternative mRNA Splicing Events in Cervical Cancer.

Authors:  Xiang-Yang Shao; Jin Dong; Han Zhang; Ying-Song Wu; Lei Zheng
Journal:  Front Genet       Date:  2020-07-10       Impact factor: 4.599

4.  Aspects of Therapy for Cervical Cancer in Germany 2012 - Results from a Survey of German Gynaecological Hospitals.

Authors:  M Mangler; N Zech; A Schneider; C Köhler; S Marnitz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

5.  Prognostic evaluation of postoperative adjuvant therapy for operable cervical cancer: 10 years' experience of National Cancer Center in China.

Authors:  Tong Shu; Dan Zhao; Bin Li; Yating Wang; Shuanghuan Liu; Pingping Li; Jing Zuo; Ping Bai; Rong Zhang; Lingying Wu
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

6.  Validation of tumour-free distance as novel prognostic marker in early-stage cervical cancer: a retrospective, single-centre, cohort study.

Authors:  Nicolò Bizzarri; Luigi Pedone Anchora; Gian Franco Zannoni; Vittoria Carbone; Matteo Bruno; Camilla Fedele; Valerio Gallotta; Vito Chiantera; Giacomo Avesani; Benedetta Gui; Francesco Fanfani; Anna Fagotti; Giovanni Scambia; Gabriella Ferrandina
Journal:  Br J Cancer       Date:  2021-04-14       Impact factor: 7.640

7.  Cost-utility analysis of treatments for stage IB cervical cancer.

Authors:  Kanyarat Katanyoo; Naiyana Praditsitthikorn; Siriwan Tangjitgamol; Sumonmal Manusirivithaya; Busaba Supawattanabodee
Journal:  J Gynecol Oncol       Date:  2014-04-09       Impact factor: 4.401

8.  Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study.

Authors:  S Y Ryu; M H Kim; B H Nam; T S Lee; E S Song; C Y Park; J W Kim; Y B Kim; H S Ryu; S Y Park; K T Kim; C H Cho; C Lee; S M Kim; B G Kim; D S Bae; Y T Kim; J-H Nam
Journal:  Br J Cancer       Date:  2013-12-19       Impact factor: 7.640

9.  Cisplatin concurrent chemoradiotherapy vs adjuvant radiation in stage IB/IIA cervical cancer with intermediate risk factors, treated with radical surgery: a retrospective study.

Authors:  Hai-Yan Sun; Qiu Tang; Jian-Hong Chen; Xiao-Juan Lv; Ye-Qiang Tu; Ding-Ding Yan
Journal:  Onco Targets Ther       Date:  2018-03-06       Impact factor: 4.147

10.  Chemotherapy versus radiotherapy for FIGO stages IB1 and IIA1 cervical carcinoma patients with postoperative isolated deep stromal invasion: a retrospective study.

Authors:  Lei Li; XiaoYan Song; RuoNan Liu; Nan Li; Ye Zhang; Yan Cheng; HongTu Chao; LiYing Wang
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.